← back to search

Gerald F. Watts

Harvard University · US
Area of research
Surgery · Endocrinology, Diabetes and Metabolism
Research interest
Research interests include Lipoproteins and Cardiovascular Health, Diabetes, Cardiovascular Risks, and Lipoproteins, Cancer, Lipids, and Metabolism, and Lipid metabolism and disorders.
h-index
125
citations
72,159
works
1,432
NIH funding
primary concept
email

Recent publications

Association of cardiovascular risk scores with coronary plaque and its progression among individuals with family history of coronary artery disease.
2026cited by 0position: selecteddoi
Association of leukocyte count with atherosclerotic cardiovascular disease in patients with genetically defined familial hypercholesterolaemia.
2026cited by 0position: selecteddoi
Attainment of Low-Density Lipoprotein Cholesterol Goals and Statin Use in Patients With Atherosclerotic Cardiovascular Disease in Australian General Practice: Are We Doing Enough?
2026cited by 0position: selecteddoi
Barriers and Facilitators to Implementing Guideline Recommendations for Key Aspects of Familial Hypercholesterolemia Management in Australia: Primary Care Integration, Paediatric Management, and Treatment Adherence.
2026cited by 0position: selecteddoi
Challenges in the care of women with familial hypercholesterolaemia during the reproductive period - current evidence and practical guidance.
2026cited by 0position: selecteddoi
Implementation strategies for improving the care of familial hypercholesterolaemia from the International Atherosclerosis Society: next steps in implementation science and practice
American Journal of Preventive Cardiology 2025cited by 6position: middledoi
Assessment of metabolic dysfunction‐associated fatty liver disease in primary care: a consensus statement summary
The Medical Journal of Australia 2025cited by 6position: middledoi
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
New England Journal of Medicine 2025cited by 4position: firstdoi
Palisade: Plozasiran decreases the risk of Acute Pancreatitis (AP) and may improve Quality of Life (QOL) in Familial Chylomicronemia Syndrome (FCS)
Atherosclerosis 2025cited by 0position: firstdoi
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia
JAMA Cardiology 2024cited by 148position: middledoi
Synovial fibroblast gene expression is associated with sensory nerve growth and pain in rheumatoid arthritis
Science Translational Medicine 2024cited by 61position: middledoi
Tissue-specific enhancer–gene maps from multimodal single-cell data identify causal disease alleles
Nature Genetics 2024cited by 49position: middledoi
The chromatin landscape of pathogenic transcriptional cell states in rheumatoid arthritis
Nature Communications 2024cited by 35position: middledoi
Lipidomic Risk Score to Enhance Cardiovascular Risk Stratification for Primary Prevention
Journal of the American College of Cardiology 2024cited by 32position: middledoi
Adipocyte associated glucocorticoid signaling regulates normal fibroblast function which is lost in inflammatory arthritis
Nature Communications 2024cited by 15position: middledoi
Automated multi-scale computational pathotyping (AMSCP) of inflamed synovial tissue
Nature Communications 2024cited by 7position: middledoi
Temporal Effects of Plozasiran on Lipids and Lipoproteins in Persistent Chylomicronemia
Circulation 2024cited by 6position: firstdoi
Zodasiran silences hepatic ANGPTL3 leading to deep and durable reductions in atherogenic lipids and lipoproteins in mixed dyslipidemia patients: Final results from arches-2, double-blind period
Atherosclerosis 2024cited by 1position: lastdoi
Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes
Nature 2023cited by 369position: middledoi
2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance
European Heart Journal 2023cited by 316position: middledoi
International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia
Nature Reviews Cardiology 2023cited by 213position: firstdoi
Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society
Atherosclerosis 2023cited by 140position: middledoi
RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia
NEJM Evidence 2023cited by 68position: middledoi
Mapping the dynamic genetic regulatory architecture of HLA genes at single-cell resolution
Nature Genetics 2023cited by 41position: middledoi
Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations
Heart Lung and Circulation 2023cited by 30position: middledoi
Combined population genomic screening for three high-risk conditions in Australia: a modelling study
EClinicalMedicine 2023cited by 16position: middledoi
Zhang, R. (Creator), Ng, J. (Creator), Lim, E. M. (Creator), Beilby, J. (Creator), Watts, G. (Creator) & Stuckey, B. (Creator), The University of Western Australia, 16 May 2023
2023cited by 0position: selected
Brown, S. (Creator), Ng, J. (Creator), Watts, G. (Creator), Stuckey, B. (Creator), Beilby, J. (Creator), Lim, E. M. (Creator) & Zhang, R. (Creator), The University of Western Australia, 10 May 2023
2023cited by 0position: selected
Brown, S. (Creator), Ng, J. (Creator), Stuckey, B. (Creator), Watts, G. (Creator), Beilby, J. (Creator), Lim, E. M. (Creator), Zhang, R. (Creator) & Brown, S. J. (Creator), The University of Western Australia, 10 May 2023
2023cited by 0position: selected
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
European Heart Journal 2022cited by 1,239position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Robert A. Hegele · Western University11 papers (2013–2025)Raúl D. Santos · Universidade de São Paulo11 papers (2013–2025)Éric Bruckert · Sorbonne Université10 papers (2013–2023)Kausik K. Ray · Imperial College London9 papers (2013–2025)Frederick J. Raal · Mayo Clinic in Arizona9 papers (2013–2025)David Sullivan · Royal Prince Alfred Hospital9 papers (2013–2023)Daniel Gaudet · Thrombolysis in Myocardial Infarction Study Group8 papers (2020–2025)Alberico L. Catapano · Novo Nordisk (United Kingdom)8 papers (2013–2023) · 7 papers (2013–2025)Klaus G. Parhofer · LMU Klinikum7 papers (2013–2023)Peter P. Tóth · University of Debrecen7 papers (2013–2019)Børge G. Nordestgaard · University College Copenhagen6 papers (2012–2023)Erik S.G. Stroes · Amsterdam University of Applied Sciences6 papers (2013–2023)Shizuya Yamashita · Université Claude Bernard Lyon 16 papers (2013–2025)Samuel S. Gidding · Genomic Health (United States)6 papers (2013–2025)Gerald F. Watts · Central Queensland University5 papers (2020–2026)Amirhossein Sahebkar · Mashhad University of Medical Sciences5 papers (2015–2019)Maciej Banach · University of Southampton5 papers (2015–2019)Christie M. Ballantyne · New York University5 papers (2020–2024)Ira J. Goldberg · NYU Langone Health5 papers (2020–2025)